Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q4 CY2024 results , with sales up 14.6% year on year to ...

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $178 from $177 and keeps an Outperform rating on the shares following the ...

In a report released on January 31, Elizabeth Anderson CFA from Evercore ISI maintained a Hold rating on Quest Diagnostics (DGX – Research ...

Following the earnings announcement, Quest Diagnostics (NYSE:DGX)' stock price rose by 0.48% in pre-market trading. The stock ...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, ...

This was the stock's second consecutive day of losses.

Shares of Quest Diagnostics Inc. DGX shed 1.78% to $157.13 Tuesday, on what proved to be an all-around favorable trading ...

"Seeing is believing," the founder of lab company Truvian told me. So I tried its tabletop blood testing device—which ...

VANCOUVER, BC, CANADA, January 20, 2025 /EINPresswire / -- The MRD Testing market is expected to grow from an estimated USD 1351.5 million in 2024 to USD 3901.1 million in 2033, at a CAGR of 12.50%.

Avestar Capital LLC raised its holdings in Quest Diagnostics by 1.1% in the third quarter. Avestar Capital LLC now owns 6,288 shares of the medical research company’s stock valued at $976,000 ...